肿瘤坏死因子相关凋亡诱导配体(TRAIL)是TNF超家族新成员。TRAIL能选择性诱导肿瘤细胞凋亡,而对正常细胞无明显毒性作用,故作为一种新型的肿瘤治疗生物制剂,具有良好的临床应用前景。但目前大量研究证明白血病细胞对TRAIL的诱导凋亡作用不敏感,其具体机制是近几年来肿瘤凋亡的 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a new member of the TNF superfamily. TRAIL can selectively induce apoptosis of tumor cells, but has no obvious toxic effect on normal cells. Therefore, TRAIL has good clinical application prospects as a new type of biological agents for tumor therapy. However, a large number of studies have shown that leukemia cells are not sensitive to the induction of apoptosis induced by TRAIL. The specific mechanism is that the apoptosis of the tumor in recent years